BTIG Research Issues Positive Forecast for Enovis (NYSE:ENOV) Stock Price

Enovis (NYSE:ENOV) had its target price lifted by BTIG Research from $41.00 to $43.00 in a report issued on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research firms have also recently weighed in on ENOV. Canaccord Genuity Group cut their price objective on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. Evercore reissued an “outperform” rating on shares of Enovis in a report on Monday, January 12th. Wells Fargo & Company boosted their price objective on shares of Enovis from $41.00 to $42.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Finally, UBS Group reaffirmed a “buy” rating and set a $50.00 price target on shares of Enovis in a research report on Monday, January 5th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Enovis has an average rating of “Moderate Buy” and a consensus price target of $47.43.

Enovis Stock Up 13.8%

Enovis stock opened at $25.39 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.22 and a quick ratio of 1.16. The company’s 50-day moving average is $24.30 and its 200-day moving average is $28.21. The firm has a market capitalization of $1.45 billion, a PE ratio of -1.07 and a beta of 1.52. Enovis has a fifty-two week low of $21.00 and a fifty-two week high of $40.69.

Enovis (NYSE:ENOV) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.14. The business had revenue of $575.76 million during the quarter, compared to the consensus estimate of $584.30 million. Enovis had a positive return on equity of 7.79% and a negative net margin of 61.22%.The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.98 EPS. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Sell-side analysts anticipate that Enovis will post 2.79 earnings per share for the current year.

Insider Activity at Enovis

In related news, EVP Daniel A. Pryor sold 999 shares of Enovis stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $27.20, for a total transaction of $27,172.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 2.70% of the company’s stock.

Institutional Trading of Enovis

Several hedge funds have recently added to or reduced their stakes in the stock. McIlrath & Eck LLC lifted its stake in Enovis by 6.9% in the third quarter. McIlrath & Eck LLC now owns 5,517 shares of the company’s stock valued at $167,000 after purchasing an additional 357 shares during the last quarter. Farther Finance Advisors LLC lifted its stake in Enovis by 42.8% during the third quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after purchasing an additional 367 shares during the last quarter. Teacher Retirement System of Texas grew its position in Enovis by 6.1% during the second quarter. Teacher Retirement System of Texas now owns 8,664 shares of the company’s stock valued at $272,000 after acquiring an additional 495 shares during the last quarter. Amalgamated Bank lifted its stake in Enovis by 3.6% in the third quarter. Amalgamated Bank now owns 16,793 shares of the company’s stock worth $509,000 after purchasing an additional 585 shares during the last quarter. Finally, Heritage Family Offices LLP boosted its holdings in Enovis by 8.9% during the 3rd quarter. Heritage Family Offices LLP now owns 7,598 shares of the company’s stock valued at $231,000 after acquiring an additional 620 shares during the period. Institutional investors own 98.45% of the company’s stock.

Enovis News Summary

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q4 adjusted earnings outpaced estimates — Enovis reported adjusted EPS of $0.95 (beat vs. ~$0.81 consensus), signaling underlying operating profitability despite GAAP noise. Enovis (ENOV) Q4 Earnings Beat Estimates
• Positive Sentiment: Management raised FY‑2026 EPS guidance to $3.52–3.73, above Street expectations — that upward EPS range supports a higher valuation multiple and helped sentiment. Update: Enovis Announces Fourth Quarter and Full Year 2025 Results
• Positive Sentiment: Street support: BTIG boosted its price target and kept a Buy, and a notable fund added ~$5M to a position, both signaling conviction from some investors/analysts. Benzinga (BTIG price target raise) One Fund Bet $5 Million on Enovis Stock Last Quarter. Shares Surged 14% Post‑Earnings
• Neutral Sentiment: Top‑line growth mixed: full‑year sales grew ~7% (2H momentum in Reconstructive) and Q4 net sales rose ~3%, showing commercial progress but not a breakout. Enovis Announces Fourth Quarter and Full Year 2025 Results
• Neutral Sentiment: Adjusted metrics remain healthier: adjusted EBITDA and adjusted EPS show profitable operations (adjusted EBITDA/adj. EPS materially positive), which the company highlights as the basis for its guidance. QuiverQuant summary of Enovis results
• Negative Sentiment: Revenue missed Q4 consensus ($575.8M vs. ~$584M expected) and full‑year revenue guidance (~$2.31–2.37B) sits slightly below some Street views — a headwind for growth expectations. Enovis beats earnings but misses on revenue
• Negative Sentiment: Large non‑cash goodwill impairment ($501M Q4, $1.05B FY) produced a substantial GAAP net loss (Q4 and FY), weakening headline earnings, accumulated deficit and some balance‑sheet metrics — a risk for longer‑term investor confidence. QuiverQuant (impairment and GAAP loss details)

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.